NOV 06, 2013
Nicox S.A. reported revenues of €0.3 million for the nine months ended Sept. 30, compared to €7.6 million for the corresponding period of 2012, which included a milestone payment from Bausch & Lomb. The company recorded a total net loss of €13.6 million for the nine months ending on September 30 of this year compared to a net loss of €4.6 million for the same period in 2012.
Selling, administrative and research and development costs were €13.6 million for the first nine months of 2013, with 43 percent of these costs related to selling expenses, reflecting the transformation of Nicox into a commercial ophthalmic company. This compares to €11.6 million for the same period in 2012.
The company reported that during the third quarter of 2013 it made progress in strengthening its commercial organization in France, Italy, the UK, Germany and Spain, where it plans to launch AdenoPlus, its first diagnostic test in-licensed from RPS, as well as a line of eye care products sourced from a European partner.
In the U.S., Nicox is preparing to launch its second diagnostic test by the end of the year, the Dry Eye Panel for Sjögren’s Syndrome, as part of its exclusive agreement with Immco Diagnostics Inc.